Telesis Bio Incの収益Y / Y
Telesis Bio Incの収益Y / Yは何ですか。
Telesis Bio Incの収益Y / Yは-43.65%です。
収益Y / Yの定義は何ですか。
過去3年間の年間収益の伸びは、過去3年間で平均した1年間の収益成長率です。
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
NASDAQのセクタHealth Careにおける収益Y / Yの企業と比べるTelesis Bio Inc
Telesis Bio Incは何をしますか。
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Incと類似の収益y / y
- WhiteHawkの収益Y / Yは-44.03%です。
- Gujarat Fluorochemicalsの収益Y / Yは-43.96%です。
- Medifast Incの収益Y / Yは-43.90%です。
- Hallmark Services, Incの収益Y / Yは-43.85%です。
- Cheniereの収益Y / Yは-43.83%です。
- Mobilicomの収益Y / Yは-43.79%です。
- Telesis Bio Incの収益Y / Yは-43.65%です。
- Clene Nanomedicineの収益Y / Yは-43.62%です。
- Shandong Molong Petroleum Machineryの収益Y / Yは-43.62%です。
- Protalix BioTherapeuticsの収益Y / Yは-43.59%です。
- Core Economy Investmentの収益Y / Yは-43.56%です。
- Hindustan Copperの収益Y / Yは-43.55%です。
- Poseida Therapeuticsの収益Y / Yは-43.55%です。